Delving into the Latest Updates on 苏州赞荣医药科技有限公司 with Synapse

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.
The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

开始日期2020-10-15

申办/合作机构

苏州赞荣医药科技有限公司

NCT05593094

/ Recruiting临床1期

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

开始日期2020-10-15

申办/合作机构

苏州赞荣医药科技有限公司

100 项与苏州赞荣医药科技有限公司相关的临床结果

登录后查看更多信息

0 项与苏州赞荣医药科技有限公司相关的专利（医药）

登录后查看更多信息

100 项与苏州赞荣医药科技有限公司相关的药物交易

登录后查看更多信息

100 项与苏州赞荣医药科技有限公司相关的转化医学

登录后查看更多信息